T-tau and p-tau were suggested as potential biomarkers for the detection of cognitive impairments in PD patients along with other CSF biomarkers like Aβ1–42 and α-syn (Chen et al. 2020). The gene discussed is MAPT; the disease is Cognitive impairment.